Anzeige
Meldung des Tages: Spark Energy Minerals: warum diese Aktie jetzt besonders interessant ist!

Nektar Therapeutics News

Aktie
WKN:  A419UB ISIN:  US6402683063 US-Symbol:  NKTR Branche:  Biotechnologie Land:  USA
68,66 $
+3,21 $
+4,90%
58,096 € 27.02.26
Depot/Watchlist
Marktkapitalisierung *
7,03 Mrd. €
Streubesitz
27,94%
KGV
-5,04
Index-Zuordnung
-

Nektar Therapeutics News

26.02.26 - PR Newswire
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Fourth Quarter and Year-​Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets PR Newswire
24.02.26 - PR Newswire
Nektar Therapeutics to Participate in Two Investor Conferences in March
Nektar Therapeutics to Participate in Two Investor Conferences in March PR Newswire
17.02.26 - PR Newswire
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple ...
13.02.26 - PR Newswire
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
11.02.26 - PR Newswire
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering PR Newswire
10.02.26 - PR Newswire
Nektar Therapeutics Announces Proposed Public Offering
Nektar Therapeutics Announces Proposed Public Offering PR Newswire
10.02.26 - PR Newswire
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
New REZOLVE-​AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with ...
09.02.26 - PR Newswire
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-​AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on ...
30.01.26 - PR Newswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
22.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR PR Newswire
15.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR PR Newswire
08.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR PR Newswire
01.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR PR Newswire
16.12.25 - PR Newswire
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
REZOLVE-​AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-​of-Concept in Patients with Severe-​to-Very-Severe Alopecia Areata PR Newswire
15.12.25 - PR Newswire
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-​AA Phase 2b Study of Rezpegaldesleukin in Alopecia ...
05.12.25 - PR Newswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.11.25 - PR Newswire
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
New Data from REZOLVE-​AD Study of Rezpegaldesleukin Presented in Late-​Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting PR Newswire
06.11.25 - PR Newswire
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
Nektar Therapeutics Reports Third Quarter 2025 Financial Results PR Newswire
30.10.25 - PR Newswire
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London PR Newswire
28.10.25 - PR Newswire
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets PR Newswire

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »